United Therapeutics Corporation (UTHR) Getting Somewhat Positive News Coverage, Study Shows
News stories about United Therapeutics Corporation (NASDAQ:UTHR) have been trending somewhat positive recently, AlphaOne Sentiment Analysis reports. The research firm, a subsidiary of Accern, scores the sentiment of press coverage by reviewing more than 20 million blog and news sources. AlphaOne ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. United Therapeutics Corporation earned a coverage optimism score of 0.10 on AlphaOne’s scale. AlphaOne also assigned press coverage about the biotechnology company an impact score of 72 out of 100, indicating that recent press coverage is likely to have an effect on the company’s share price in the next several days.
These are some of the headlines that may have effected Alpha One Sentiment’s rankings:
- Tale of the Ticker: United Therapeutics Corp (UTHR) Moves on Volume – Financial News Review (finnewsreview.com)
- United Therapeutics Corporation (UTHR) Upgraded to Hold by BidaskClub (americanbankingnews.com)
- Zacks: Brokerages Expect United Therapeutics Corporation (UTHR) Will Post Quarterly Sales of $404.01 Million (americanbankingnews.com)
- Silver Spring tissue regeneration company raises $12 million (finance.yahoo.com)
- United Therapeutics Co. (UTHR) Expected to Post Earnings of $3.61 Per Share (americanbankingnews.com)
Several brokerages recently weighed in on UTHR. Oppenheimer Holdings, Inc. reissued a “buy” rating on shares of United Therapeutics Corporation in a research report on Monday, April 3rd. Cowen and Company reissued a “hold” rating and set a $121.00 price target on shares of United Therapeutics Corporation in a research report on Wednesday, April 26th. Jefferies Group LLC cut shares of United Therapeutics Corporation from a “hold” rating to an “underperform” rating and dropped their target price for the stock from $149.47 to $116.00 in a report on Monday, March 6th. HC Wainwright restated a “hold” rating and issued a $95.00 target price on shares of United Therapeutics Corporation in a report on Monday, April 17th. Finally, Ladenburg Thalmann Financial Services cut shares of United Therapeutics Corporation from a “buy” rating to a “neutral” rating and set a $145.00 target price on the stock. in a report on Thursday, February 23rd. Three research analysts have rated the stock with a sell rating, nine have issued a hold rating and three have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $137.09.
United Therapeutics Corporation (NASDAQ UTHR) traded down 0.43% on Friday, hitting $129.92. 578,775 shares of the company were exchanged. The firm’s 50 day moving average is $124.34 and its 200 day moving average is $138.37. The company has a market capitalization of $5.85 billion, a P/E ratio of 9.12 and a beta of 1.56. United Therapeutics Corporation has a 52 week low of $97.52 and a 52 week high of $169.89.
United Therapeutics Corporation (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, April 26th. The biotechnology company reported $3.89 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.12 by $0.77. The company had revenue of $370.50 million for the quarter, compared to analysts’ expectations of $399.59 million. United Therapeutics Corporation had a net margin of 41.04% and a return on equity of 34.74%. United Therapeutics Corporation’s revenue was up .4% compared to the same quarter last year. During the same period in the previous year, the company posted $3.02 EPS. On average, equities research analysts forecast that United Therapeutics Corporation will post $14.42 earnings per share for the current fiscal year.
In other news, Director Tommy G. Thompson sold 2,000 shares of the company’s stock in a transaction on Wednesday, March 22nd. The shares were sold at an average price of $139.37, for a total transaction of $278,740.00. Following the transaction, the director now directly owns 2,000 shares of the company’s stock, valued at approximately $278,740. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Martine A. Rothblatt sold 1,219 shares of the company’s stock in a transaction on Thursday, March 23rd. The stock was sold at an average price of $139.33, for a total transaction of $169,843.27. Following the transaction, the chief executive officer now directly owns 1,359 shares in the company, valued at $189,349.47. The disclosure for this sale can be found here. Insiders sold a total of 17,020 shares of company stock worth $2,154,373 over the last three months. 7.50% of the stock is currently owned by corporate insiders.
United Therapeutics Corporation Company Profile
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).
Receive News & Stock Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related stocks with our FREE daily email newsletter.